Screener
Dianthus Therapeutics DNTH Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Dianthus Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
FAQ
- What is Dianthus Therapeutics's debt-to-equity?
- Dianthus Therapeutics (DNTH) reported debt-to-equity of 0× in Q1 2026.
- How has Dianthus Therapeutics's debt-to-equity changed year-over-year?
- Dianthus Therapeutics's debt-to-equity decreased by 73.8% year-over-year, from 0× to 0×.
- What is the long-term trend for Dianthus Therapeutics's debt-to-equity?
- Over 2 years (2023 to 2025), Dianthus Therapeutics's debt-to-equity has grown at a -10.6% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Dianthus Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude